Pfizer

Pfizer reported third-quarter adjusted EPS of $0.87 and revenue of $16.58 billion, both above consensus, and raised its full-year revenue outlook to $62–64 billion. The company also raised full-year adjusted EPS guidance to $2.95–3.05. Cecile Guegan, a long-time finance executive who served as interim CFO since August, has been named chief financial officer. Management cited strong year-to-date performance and ongoing cost cuts as drivers of the outlook improvement. » Mere på cnbc.com

Pfizer’s dividend yields about 6.2%, one of the highest in the S&P 500, and its trailing 12‑month free cash flow of nearly $11 billion exceeds roughly $9.8 billion in cash dividends, supporting payout sustainability. The company is cutting expenses to strengthen finances as it navigates its next growth phase. By contrast, Eli Lilly offers minimal yield (~0.6%) but has delivered rapid dividend growth driven by strong GLP‑1 profits, making Lilly a growth-plus-income option while Pfizer suits yield-focused investors. » Mere på finance.yahoo.com

A largely redacted contract shows that Pfizer must hand over part of additional net revenues from higher drug prices abroad to the U.S. Department of Health and Human Services (HHS). The agreement runs from January 1, 2026, to January 20, 2029; the percentage rate, the drugs affected and the allocation of the funds are secret. Pfizer stresses its contribution to relieving U.S. patients, analysts view the deal as politically advantageous for the company, while other markets could be burdened by higher prices. » Mere på deraktionaer.de

CEO Albert Bourla says Pfizer has addressed tariff and pricing pressures and COVID product declines are less impactful, while the company has beaten EPS estimates in recent quarters. Pfizer reports $13 billion in annualized revenue from newer and acquired products and has cut about $7.2 billion in costs to help offset upcoming patent expirations. Major risks remain as Eliquis and Ibrance face U.S. patent cliffs in 2028 and 2027 respectively, but management expects oncology and weight‑loss programs plus other pipeline assets to deliver launches by the end of the decade. Pfizer maintains a high forward dividend yield (6.2%) and is likely to keep payouts intact while revenue may dip in the near term as patent losses are navigated. » Mere på finance.yahoo.com

The EMA has validated the marketing application for PF-07307405, the Pfizer–Valneva Lyme vaccine, and begun formal review. The submission is based on the Phase 3 VALOR trial showing >70% efficacy and no safety signals, but the primary prespecified analysis missed its predefined statistical confidence-bound threshold while a second analysis met it. Approval would leave the partners with little direct competition in Europe, but review timelines, pricing and commercialization details remain uncertain and the market reaction was muted. » Mere på finance.yahoo.com